z-logo
open-access-imgOpen Access
HOGA1 Gene Mutations of Primary Hyperoxaluria Type 3 in Tunisian Patients
Author(s) -
M'dimegh Saoussen,
Aquavivabourdain Cécile,
Omezzine Asma,
Souche Geneviéve,
M'barek Ibtihel,
Abidi Kamel,
Gargah Tahar,
Abroug Saoussen,
Bouslama Ali
Publication year - 2017
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22053
Subject(s) - nephrocalcinosis , primary hyperoxaluria , multiplex ligation dependent probe amplification , mutation , renal function , gastroenterology , medicine , genetics , gene , gene mutation , compound heterozygosity , kidney , biology , exon
Background Primary hyperoxaluria type 3 ( PH 3) is due to mutations in the recently identified 4‐hydroxy‐2‐oxoglutarate aldolase ( HOGA 1 ) gene. PH 3 might be the least severe form with a milder phenotype with good preservation of kidney function in most patients. The aim of this study was to report three PH 3 cases carrying mutations in HOGA 1 . Materials and Methods Genetic analysis of HOGA 1 was performed in patients with a high clinical suspicion of PH after sequencing of AGXT and GRHPR genes, which was negative. Also, a complete AGXT / GRHPR MLPA was performed in these patients in order to detect large deletions/insertions. Results and Discussion Two different HOGA 1 gene mutations were identified: the p.Pro190Leu in a homozygous state and the p.Gly287Val in two patients in homozygous and heterozygous carriers. The median age at onset of clinical symptoms was 3.93 years. Most of the patients had a positive family history for recurrent urolithiasis. The p.Pro190Leu mutation was reported with impaired renal function at follow‐up; however, the p.Gly287Val was presented with normal renal function. All patients were presented with urolithiasis, but only one had a nephrocalcinosis. Conclusion This study expanded the number of PH 3 patients from 63 to 66 cases. The p.Pro190Leu and the p.Gly287Val mutations found in this study can provide a first‐line investigation in Tunisian PH 1 patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom